ENDPOINTS

AbbVie's Venclexta fails Phase 3 study in other bone marrow cancers

AbbVie said Venclexta did not improve survival in patients with myelodysplastic syndromes when combined with another commonly prescribed drug. The drugmaker announced Monday that Venclexta combined with azacitidine did not improve ...

Jun 16, 2025 - 16:30
 0
AbbVie's Venclexta fails Phase 3 study in other bone marrow cancers
AbbVie said Venclexta did not improve survival in patients with myelodysplastic syndromes when combined with another commonly prescribed drug. The drugmaker announced Monday that Venclexta combined with azacitidine did not improve ...
Read More

Tags:

Previous Article

Oldest known dinosaur bone infection found in 220-million-year-old Plateosaurus

Next Article

Graduate Students Push Back Against Science Funding Cuts

Related Posts

#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise

#ASGCT25: In three patients, Rocket’s second heart gene...

May 16, 2025  0

Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100M

Vera redraws the terms of up to $500M credit facility; ...

Jun 3, 2025  0

Movement disorder biotech Vima steps onto scene with $60M

Movement disorder biotech Vima steps onto scene with $60M

May 29, 2025  0